Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07018323 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
A Phase 2 study of Graves Disease, sponsored by Immunovant Sciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 210
- Enrollment target
- 20
- Study locations
NCT07018323: Recruiting Phase 2 study of Graves Disease, sponsored by Immunovant Sciences.
NCT07018323 is a Phase 2 study of Graves Disease that is actively recruiting participants, run by Immunovant Sciences. The registered enrollment target is 210 participants, below the 291-participant average among 11 other Graves Disease trials with a reported enrollment target (28% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07018323, a Phase 2 study of Graves Disease, is actively recruiting participants, sponsored by Immunovant Sciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 210 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multi-center, global, randomized, double-blind, placebo-controlled Phase 2b study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG IMVT-1402
Study Locations (20)
New York
- Site Number - 1032 - Long Island City
- Site Number - 1027 - New Hyde Park
- Site Number - 1009 - New York
- Site Number - 1018 - Williamsville
North Carolina
- Site Number - 1010 - Chapel Hill
- Site Number - 1026 - Hickory
- Site Number - 1001 - Morehead City
- Site Number - 1034 - Raleigh
Florida
- Site Number - 1024 - Doral
- Site Number - 1008 - Hialeah
- Site Number - 1000 - Miami
Missouri
- Site Number - 1033 - Jefferson City
- Site Number - 1004 - Kansas City
- Site Number - 1019 - St Louis
Arizona
- Site Number - 1015 - Tucson
California
- Site Number -1014 - Concord
Colorado
- Site Number - 1013 - Aurora
Georgia
- Site Number - 1020 - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2025-06-19 |
| Est. Completion | 2027-05 |
| Phase | Phase 2 |
What NCT07018323 shows while recruiting
NCT07018323 is an interventional study that assigns participants to a tested intervention. The registered 210 participants enrollment target is mid-sized for trials with a published cap, below the 291-participant average among 11 other Graves Disease trials with a reported enrollment target (28% lower).
The record links to 1 condition, with Graves Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07018323 names 20 study sites across 10 states, led by New York, North Carolina, Florida.
Frequently Asked Questions
What is clinical trial NCT07018323 about?
NCT07018323 is a clinical study titled "A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease". This is a multi-center, global, randomized, double-blind, placebo-controlled Phase 2b study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.
What is the current status of trial NCT07018323?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 210 participants. The study started on 2025-06-19. Estimated completion is 2027-05.
What conditions does trial NCT07018323 study?
This clinical trial studies the following conditions: Graves Disease.
What interventions are being tested in trial NCT07018323?
The interventions under investigation include: Placebo (DRUG), IMVT-1402 (DRUG).
Who is sponsoring clinical trial NCT07018323?
This trial is sponsored by Immunovant Sciences, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07018323 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Graves Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07018323's enrollment target sits among peer trials
210 3rd of 11 higher than 9 of 11 other Graves Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Graves Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease
RECRUITING · Phase 2
-
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
RECRUITING · Phase 2
-
Radioactive Iodide Therapy for Pediatric Graves' Disease
COMPLETED · Phase 2
-
A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease
COMPLETED · Phase 2
-
NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease
RECRUITING · Phase 1
-
Study of BHV-1300 in Graves' Disease
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02665923 · 210 participants
Gastric Emptying in Neonates and Infants After Formula Feeding
- NCT03322891 · 210 participants · NA
Improving Health Literacy in African-American Prostate Cancer Patients
- NCT03544489 · 210 participants · Phase 2
Effectiveness of Exercise After an ICD
- NCT04408430 · 210 participants · NA
The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI